Padmapriya Sathiyanathan

Padmapriya Sathiyanathan

Auto-generated profile, based on publicly available information

Padmapriya Sathiyanathan

Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2015 in Stem Cells
Verified
Journal Article
Open access
PDF file
RSRebekah Margaret Samsonraj
Rebekah Margaret Samsonraj
BRBina Rai
Bina Rai
PSPadmapriya Sathiyanathan
Padmapriya Sathiyanathan
KPKia Joo Puan
Kia Joo Puan
OROlaf Rötzschke
Olaf Rötzschke
SCSimon M. Cool
Simon M. Cool
This study sought to identify critical determinants of mesenchymal stem cell (MSC) potency using in vitro and in vivo attributes of cells isolated from the bone marrow of age- and sex-matched donors. Adherence to plastic was not indicative of potency, yet capacity for long-term expansion in vitro varied considerably between donors, allowing the grouping of MSCs from the donors into either those with high-growth capacity or low-growth capacity. Using this grouping strategy, high-growth capacity MSCs were smaller in size, had greater colony-forming efficiency, and had longer telomeres. Cell-surface biomarker analysis revealed that the International Society for Cellular Therapy (ISCT) criteria did not distinguish between high-growth capacity and low-growth capacity MSCs, whereas STRO-1 and platelet-derived growth factor receptor alpha were preferentially expressed on high-growth capacity MSCs. These cells also had the highest mean expression of the mRNA transcripts TWIST-1 and DERMO-1. Irrespective of these differences, both groups of donor MSCs produced similar levels of key growth factors and cytokines involved in tissue regeneration and were capable of multilineage differentiation. However, high-growth capacity MSCs produced approximately double the volume of mineralized tissue compared to low-growth capacity MSCs when assessed for ectopic bone-forming ability. The additional phenotypic criteria presented in this study when combined with the existing ISCT minimum criteria and working proposal will permit an improved assessment of MSC potency and provide a basis for establishing the quality of MSCs prior to their therapeutic application. Stem Cells 2015;33:1878–1891

21 May 2009 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
HSHeike Summer
Heike Summer
OLOu Li
Ou Li
QBQiuye Bao
Qiuye Bao
LZLihong Zhan
Lihong Zhan
SPSabrina Peter
Sabrina Peter
Peter DrögePeter Dröge
Peter Dröge
HMGA proteins are not translated in normal human somatic cells, but are present in high copy numbers in pluripotent embryonic stem cells and most neoplasias. Correlations between the degree of malignancy, patient prognostic index and HMGA levels have been firmly established. Intriguingly, HMGA2 is also found in rare tumor-inducing cells which are resistant to chemotherapy. Here, we demonstrate that HMGA1a/b and HMGA2 possess intrinsic dRP and AP site cleavage activities, and that lysines and arginines in the AT-hook DNA-binding domains function as nucleophiles. We also show that HMGA2 can be covalently trapped at genomic abasic sites in cancer cells. By employing a variety of cell-based assays, we provide evidence that the associated lyase activities promote cellular resistance against DNA damage that is targeted by base excision repair (BER) pathways, and that this protection directly correlates with the level of HMGA2 expression. In addition, we demonstrate an interaction between human AP endonuclease 1 and HMGA2 in cancer cells, which supports our conclusion that HMGA2 can be incorporated into the cellular BER machinery. Our study thus identifies an unexpected role for HMGA2 in DNA repair in cancer cells which has important clinical implications for disease diagnosis and therapy.

25 February 2022 in Cytotherapy
Verified
Journal Article
Closed access
ASAkshaya Srinivasan
Akshaya Srinivasan
PSPadmapriya Sathiyanathan
Padmapriya Sathiyanathan
LYLu Yin
Lu Yin
TLTong Ming Liu
Tong Ming Liu
ALAlan Lam
Alan Lam
SCSimon M. Cool
Simon M. Cool

25 February 2012 in Stem Cells and Development
Verified
Journal Article
Closed access
CTCheryl Y. Tay
Cheryl Y. Tay
PSPadmapriya Sathiyanathan
Padmapriya Sathiyanathan
SCStephanie W.L. Chu
Stephanie W.L. Chu
LSLawrence W. Stanton
Lawrence W. Stanton
TWTina T. Wong
Tina T. Wong
Mesenchymal stem cells (MSC) have been isolated from several adult human tissues. Their propensity to differentiate into cell types of connective tissue, such as osteocytes, chondrocytes, and adipocytes, suggests that MSC may function as a reserve of progenitor cells that repair and maintain healthy adult tissues. Dysfunction of the trabecular meshwork (TM), a connective tissue at the anterior region of the human eye that regulates intraocular pressure, plays a major role in the pathogenesis of glaucoma. The mechanobiology and pharmacological aspects of the TM tissue have been relatively well studied in disease states. Less well understood is if there are progenitor cells within the TM that contribute to maintenance of this tissue. In this study, we have identified and characterized an expandable population of cells that have stem cell-like properties. In particular, these cells express the markers CD73, CD90, and CD105, which are typically associated with MSC. Thus, we have named these cells TM-MSC. As further evidence that these cells are MSC, they were differentiated in vitro into adipocytes, osteocytes, and chondrocytes. Through genomic characterization, we show that TM-MSC have gene expression patterns most similar to MSC derived from other tissues. TM-MSC express genes found on adult TM tissue, suggesting that TM-MSC are progenitor cells that serve to maintain a healthy TM.

1 February 2014 in Cell Reports
Verified
Journal Article
Open access
HYHaojie Yu
Haojie Yu
HLHong Hwa Lim
Hong Hwa Lim
NTNatalia O. Tjokro
Natalia O. Tjokro
PSPadmapriya Sathiyanathan
Padmapriya Sathiyanathan
SNSuchitra Natarajan
Suchitra Natarajan
Peter DrögePeter Dröge
Peter Dröge
Maintaining genome integrity requires the accurate and complete replication of chromosomal DNA. This is of the utmost importance for embryonic stem cells (ESCs), which differentiate into cells of all lineages, including germ cells. However, endogenous and exogenous factors frequently induce stalling of replication forks in every cell cycle, which can trigger mutations and chromosomal instabilities. We show here that the oncofetal, nonhistone chromatin factor HMGA2 equips cells with a highly effective first-line defense mechanism against endonucleolytic collapse of stalled forks. This fork-stabilizing function most likely employs scaffold formation at branched DNA via multiple DNA-binding domains. Moreover, HMGA2 works independently of other human factors in two heterologous cell systems to prevent DNA strand breaks. This fork chaperone function seemingly evolved to preserve ESC genome integrity. It is hijacked by tumor (stem) cells to also guard their genomes against DNA-damaging agents widely used to treat cancer patients.

8 June 2020 in Stem Cells
Verified
Journal Article
Open access
PDF file
PSPadmapriya Sathiyanathan
Padmapriya Sathiyanathan
RSRebekah Margaret Samsonraj
Rebekah Margaret Samsonraj
CTClarissa L. L. Tan
Clarissa L. L. Tan
LLLing Ling
Ling Ling
ALAlexander Lezhava
Alexander Lezhava
SCSimon M. Cool
Simon M. Cool
Although the application of human mesenchymal stem cells (hMSCs) to repair damaged or diseased tissues has proven relatively effective, both the donor-to-donor variability in ex vivo expansion rates and the maintenance of stemness remain a bottleneck to widespread translation. Previous work from this laboratory stratified donors into those yielding hMSCs with high- or low-growth capacity; global transcriptomic analysis revealed that high-growth-capacity hMSCs were characterized by a loss of the gene encoding glutathione S-transferase theta 1 (GSTT1). These GSTT1-null hMSCs demonstrated increased proliferative rates, clonogenic potential, and longer telomeres compared with low-growth capacity hMSCs that were GSTT1-positive. Thus, this study identifies GSTT1 as a novel genomic DNA biomarker for hMSC scalability.